Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

RPRX

Royalty Pharma plc

Dec 20 • 04:00PM ET

24.92

Dollar change +0.64
Percentage change 2.64	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB REGN VRTX GILD INCY ALNY EXEL NBIX MDGL DKNG

| Held by: VTI VO VXF VTV VOE VYM VHT IWR SCHM IWD

Scroll to Statements

Index	-	P/E	9.75	EPS (ttm)	2.56	Insider Own	14.35%	Shs Outstand	446.04M	Perf Week	0.32%
Market Cap	15.07B	Forward P/E	5.69	EPS next Y	4.38	Insider Trans	0.00%	Shs Float	380.55M	Perf Month	-4.96%
Income	1.14B	PEG	-	EPS next Q	0.98	Inst Own	70.64%	Short Float	4.13%	Perf Quarter	-10.07%
Sales	2.27B	P/S	6.65	EPS this Y	-11.36%	Inst Trans	-1.11%	Short Ratio	5.94	Perf Half Y	-8.08%
Book/sh	15.40	P/B	1.62	EPS next Y	10.36%	ROA	6.76%	Short Interest	15.70M	Perf Year	-7.94%
Cash/sh	1.65	P/C	15.09	EPS next 5Y	-1.30%	ROE	17.62%	52W Range	24.05 - 31.66	Perf YTD	-11.29%
Dividend Est.	0.68 (2.72%)	P/FCF	5.34	EPS past 5Y	2.23%	ROI	8.49%	52W High	-21.28%	Beta	0.48
Dividend TTM	0.84 (3.37%)	Quick Ratio	1.54	Sales past 5Y	5.78%	Gross Margin	-	52W Low	3.62%	ATR (14)	0.53
Dividend Ex-Date	Nov 15, 2024	Current Ratio	1.54	EPS Y/Y TTM	536.55%	Oper. Margin	68.14%	RSI (14)	38.91	Volatility	2.43% 1.88%
Employees	89	Debt/Eq	1.11	Sales Y/Y TTM	-2.52%	Profit Margin	50.52%	Recom	1.27	Target Price	41.86
Option/Short	Yes / Yes	LT Debt/Eq	0.96	EPS Q/Q	658.56%	Payout	31.57%	Rel Volume	2.87	Prev Close	24.28
Sales Surprise	5.46%	EPS Surprise	-1.09%	Sales Q/Q	5.29%	Earnings	Nov 06 BMO	Avg Volume	2.64M	Price	24.92
SMA20	-3.08%	SMA50	-5.80%	SMA200	-9.66%	Trades		Volume	7,573,804	Change	2.64%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-03-24	Downgrade	UBS	Buy → Neutral	$28
Jun-14-22	Resumed	UBS	Buy	$47
May-13-22	Initiated	Scotiabank	Sector Outperform	$53
Apr-27-22	Initiated	Goldman	Buy	$56
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight	$50
Apr-06-22	Resumed	Morgan Stanley	Overweight	$48
Oct-29-21	Upgrade	Citigroup	Neutral → Buy	$50
Jul-30-21	Initiated	Tigress Financial	Buy	$50
Nov-09-20	Upgrade	UBS	Neutral → Buy	$52 → $51
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	UBS	Neutral	$52
Jul-13-20	Initiated	SunTrust	Buy	$56
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight	$51
Jul-13-20	Initiated	JP Morgan	Neutral	$50
Jul-13-20	Initiated	Goldman	Neutral	$47
Jul-13-20	Initiated	Cowen	Outperform	$55
Jul-13-20	Initiated	Citigroup	Neutral	$50
Jul-13-20	Initiated	BofA Securities	Buy	$55

Show Previous Ratings

Dec-19-24 08:06PM	Lightning Round: MandT Bank is a buy, I like the banks, says Jim Cramer (CNBC TV)
Nov-27-24 04:15PM	Royalty Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
11:11AM	Why Royalty Pharma (RPRX) is the Cheapest Stock to Buy on Robinhood? (Insider Monkey)
Nov-14-24 04:30PM	Royalty Pharma Announces Inaugural Prize for Impact in Healthcare (GlobeNewswire)
Nov-07-24 07:10AM	Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million (GlobeNewswire)
02:10AM	Loading…
02:10AM	Royalty Pharma PLC (RPRX) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic Acquisitions (GuruFocus.com)
12:08AM	Royalty Pharma PLC (RPRX): A Strategic SWOT Insight (GuruFocus.com)
Nov-06-24 07:16PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
07:15AM	Royalty Pharma Reports Third Quarter 2024 Results (GlobeNewswire)
Nov-04-24 04:15PM	Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo (GlobeNewswire)
04:01PM	Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo (PR Newswire)
Nov-03-24 06:11AM	Morgan Stanley Predicts Up to 670% Jump for These 2 Strong Buy Stocks (TipRanks)
Oct-16-24 04:15PM	Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-11-24 08:15AM	Royalty Pharma Declares Fourth Quarter 2024 Dividend (GlobeNewswire)
Oct-09-24 05:31PM	Royalty Pharma PLC (RPRX) Q2 2024 Earnings Call Highlights: Surpassing Growth Expectations and ... (GuruFocus.com)
03:50PM	Loading…
03:50PM	Royalty Pharma plc (RPRX): Among The Stocks With Biggest Upside Potential According to Hedge Funds (Insider Monkey)
Sep-03-24 05:14PM	Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement (GlobeNewswire)
05:06PM	Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement (GlobeNewswire)
Aug-28-24 04:15PM	Royalty Pharma to Present at Morgan Stanley's 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-26-24 06:16AM	Jim Cramer on Royalty Pharma plc (NASDAQ:RPRX): Its Been a Bit of a Bust, I Feel Badly (Insider Monkey)
Aug-23-24 05:32AM	Jim Cramer's Latest Lightning Round: Top 10 Stocks (Insider Monkey)
Aug-17-24 03:58PM	Why Is Royalty Pharma plc (RPRX) the Best Defensive Stock to Buy Now? (Insider Monkey)
Aug-16-24 06:09PM	10 Best Defensive Stocks To Buy Now (Insider Monkey)
Aug-09-24 01:05AM	Royalty Pharma PLC (RPRX): A Strategic SWOT Insight (GuruFocus.com)
Aug-08-24 04:16PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
07:00AM	Royalty Pharma Reports Second Quarter 2024 Results (GlobeNewswire)
Jul-24-24 08:30AM	Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital (GlobeNewswire)
Jul-19-24 08:15AM	Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire)
Jul-17-24 04:15PM	Royalty Pharma Declares Third Quarter 2024 Dividend (GlobeNewswire)
Jul-15-24 12:10PM	Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
07:44PM	Loading…
Jul-02-24 07:44PM	Is Royalty Pharma plc (RPRX) a Good Stock to Buy Now? (Insider Monkey)
06:58PM	10 Best Undervalued Stocks To Buy Now (Insider Monkey)
Jun-26-24 06:00AM	Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024 (InvestorPlace)
Jun-24-24 12:56PM	7 Biotech Stocks to Buy on the Dip: June 2024 (InvestorPlace)
Jun-05-24 06:14AM	June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge (InvestorPlace)
Jun-04-24 04:15PM	Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-03-24 05:15PM	Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes (GlobeNewswire)
May-28-24 07:10AM	Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million (GlobeNewswire)
May-27-24 06:28PM	Is Cytokinetics, Incorporated (NASDAQ:CYTK) the Best Mid-Cap Healthcare Stock To Buy Now? (Insider Monkey)
May-25-24 11:10PM	20 Biggest Publicly Traded Biotech Companies (Insider Monkey)
May-22-24 04:10PM	Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline (GlobeNewswire)
04:00PM	Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline (GlobeNewswire)
May-20-24 02:41PM	7 Dividend Stocks to Buy at a 52-Week Low (InvestorPlace)
May-13-24 08:15AM	Royalty Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
May-10-24 01:07AM	Royalty Pharma PLC (RPRX): A Strategic SWOT Insight (GuruFocus.com)
May-09-24 03:35PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
12:00PM	Royalty Pharma (RPRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
11:56AM	RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
10:46AM	Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:10AM	Royalty Pharma (RPRX) Beats Q1 Earnings and Revenue Estimates (Zacks)
07:00AM	Royalty Pharma Reports First Quarter 2024 Results (GlobeNewswire)
06:45AM	Royalty Pharma to Acquire Royalty Interest in Sanofi's Frexalimab (GlobeNewswire)
May-08-24 08:51AM	Why Earnings Season Could Be Great for Royalty Pharma (RPRX) (Zacks)
May-06-24 09:16AM	Insights Into Royalty Pharma (RPRX) Q1: Wall Street Projections for Key Metrics (Zacks)
May-02-24 04:01PM	Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma (Business Wire)
10:01AM	Royalty Pharma (RPRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-30-24 08:37AM	PureTech Health plc (NASDAQ:PRTC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-19-24 08:15AM	Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire)
Apr-17-24 08:15AM	Royalty Pharma Declares Second Quarter 2024 Dividend (GlobeNewswire)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Feb-28-24 04:15PM	Royalty Pharma to Present at TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Feb-20-24 12:45PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Feb-17-24 12:15AM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Feb-16-24 03:30PM	Royalty Pharma (RPRX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:45AM	Royalty Pharma plc (NASDAQ:RPRX) Q4 2023 Earnings Call Transcript (Insider Monkey)
12:04AM	Royalty Pharma PLC (RPRX): A Strategic SWOT Insight (GuruFocus.com)
Feb-15-24 11:08PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
07:58AM	Royalty Pharma PLC (RPRX) Earnings Report: A Detailed Analysis (GuruFocus.com)
07:30AM	Royalty Pharma Reports Q4 and Full Year 2023 Results (GlobeNewswire)
Jan-31-24 01:04AM	What Makes Royalty Pharma plc (RPRX) a Compelling Stock? (Insider Monkey)
Jan-30-24 04:15PM	Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024 (GlobeNewswire)
Jan-19-24 08:15AM	Royalty Pharma Announces Dividend Increase (GlobeNewswire)
Jan-08-24 07:00AM	Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 05:30AM	Should You Sell Royalty Pharma plc (RPRX)? (Insider Monkey)
Nov-27-23 04:15PM	Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference (GlobeNewswire)
Nov-13-23 08:10AM	Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program (GlobeNewswire)
08:00AM	Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program (Business Wire)
Nov-09-23 04:33PM	Royalty Pharma plc (NASDAQ:RPRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:15AM	The Royalty Pharma PLC (RPRX) Company: A Short SWOT Analysis (GuruFocus.com)
Nov-08-23 07:00AM	Royalty Pharma Reports Third Quarter 2023 Results (GlobeNewswire)
Oct-19-23 07:59AM	Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi (GlobeNewswire)
Oct-16-23 04:15PM	Royalty Pharma Declares Fourth Quarter 2023 Dividend (GlobeNewswire)
Oct-11-23 04:15PM	Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023 (GlobeNewswire)
Sep-21-23 08:25AM	Royalty Pharma Appoints Eric Schneider as Chief Technology Officer (GlobeNewswire)
Sep-05-23 04:15PM	Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement (GlobeNewswire)
04:01PM	Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement (GlobeNewswire)
08:25AM	Royalty Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-24-23 06:30AM	Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg) (GlobeNewswire)
Aug-08-23 07:00AM	Royalty Pharma Reports Second Quarter 2023 Results (GlobeNewswire)
Jul-18-23 04:15PM	Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023 (GlobeNewswire)
Jul-17-23 04:15PM	Royalty Pharma Declares Third Quarter 2023 Dividend (GlobeNewswire)
Jun-18-23 08:58AM	Institutional owners may consider drastic measures as Royalty Pharma plc's (NASDAQ:RPRX) recent US$453m drop adds to long-term losses (Simply Wall St.)
Jun-07-23 08:15AM	Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
May-22-23 07:52PM	Goldman Sachs Likes These 2 Stocks, Insiders Just Poured Millions Into Them Heres Why You Might Want to Ride Their Coattails (TipRanks)
May-13-23 08:15AM	Here's Why We're Wary Of Buying Royalty Pharma's (NASDAQ:RPRX) For Its Upcoming Dividend (Simply Wall St.)
May-11-23 10:42AM	Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's (Simply Wall St.)
May-09-23 07:00AM	Royalty Pharma Reports First Quarter 2023 Results (GlobeNewswire)
May-03-23 04:15PM	Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference (GlobeNewswire)
Apr-20-23 06:15AM	Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20 (Simply Wall St.)
Apr-17-23 08:15AM	Royalty Pharma Declares Second Quarter 2023 Dividend (GlobeNewswire)

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RIGGS RORY B	Director	Jan 02 '24	Sale	28.52	235,200	6,707,081	254,899	Jan 04 05:16 PM
RIGGS RORY B	Director	Jan 03 '24	Sale	27.79	199,098	5,532,276	55,801	Jan 04 05:16 PM
RIGGS RORY B	Director	Jan 04 '24	Sale	27.55	35,702	983,504	20,099	Jan 04 05:16 PM
Avara Management Ltd	10% Owner	Dec 29 '23	Sale	28.04	65,803	1,845,406	2,477,520	Jan 03 04:31 PM
Avara Management Ltd	10% Owner	Dec 28 '23	Sale	28.20	209,863	5,918,934	2,543,323	Dec 29 04:29 PM
Avara Management Ltd	10% Owner	Dec 27 '23	Sale	28.01	41,729	1,168,754	2,753,186	Dec 29 04:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RPRX

Royalty Pharma plc

Upgrade your FINVIZ experience